Literature DB >> 3358987

Locally most powerful tests for detecting treatment effects when only a subset of patients can be expected to "respond" to treatment.

W J Conover1, D S Salsburg.   

Abstract

Two two-parameter models are developed for testing the hypothesis of no treatment effect against the alternative that a subset of the treated patients will show an improvement. To keep the range of measurements the same for treated and control patients, Lehmann alternatives are used in both models. Locally most powerful rank tests are developed for each model and each parameter. The asymptotic relative efficiency leads to a test that uses the scores s(i) = [i/(N + 1)]4. Two examples that support the usefulness of this nonparametric test are presented.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358987

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  11 in total

1.  Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients.

Authors:  C Bleul; M Müller; R Frank; H Gausepohl; U Koldovsky; H N Mgaya; J Luande; M Pawlita; J ter Meulen; R Viscidi
Journal:  J Clin Microbiol       Date:  1991-08       Impact factor: 5.948

2.  Rank transformation in Haseman-Elston regression using scores for location-scale alternatives.

Authors:  Daniel Gerhard; Ludwig A Hothorn
Journal:  Hum Hered       Date:  2009-12-18       Impact factor: 0.444

3.  A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.

Authors:  Robert W Buchanan; Richard S E Keefe; Jeffrey A Lieberman; Deanna M Barch; John G Csernansky; Donald C Goff; James M Gold; Michael F Green; L Fredrik Jarskog; Daniel C Javitt; David Kimhy; Michael S Kraus; Joseph P McEvoy; Raquelle I Mesholam-Gately; Larry J Seidman; M Patricia Ball; Robert P McMahon; Robert S Kern; James Robinson; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2010-12-08       Impact factor: 13.382

4.  Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

Authors:  Deanna L Kelly; Kelli M Sullivan; Joseph P McEvoy; Robert P McMahon; Heidi J Wehring; James M Gold; Fang Liu; Dale Warfel; Gopal Vyas; Charles M Richardson; Bernard A Fischer; William R Keller; Maju Mathew Koola; Stephanie M Feldman; Jessica C Russ; Richard S E Keefe; Jennifer Osing; Leeka Hubzin; Sharon August; Trina M Walker; Robert W Buchanan
Journal:  J Clin Psychopharmacol       Date:  2015-08       Impact factor: 3.153

5.  Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.

Authors:  Elaine Weiner; Robert R Conley; M Patricia Ball; Stephanie Feldman; James M Gold; Deanna L Kelly; Ikwunga Wonodi; Robert P McMahon; Robert W Buchanan
Journal:  Neuropsychopharmacology       Date:  2010-07-21       Impact factor: 7.853

6.  Effect of the 2010 Chilean earthquake on posttraumatic stress: reducing sensitivity to unmeasured bias through study design.

Authors:  José R Zubizarreta; Magdalena Cerdá; Paul R Rosenbaum
Journal:  Epidemiology       Date:  2013-01       Impact factor: 4.822

7.  Amplification of Sensitivity Analysis in Matched Observational Studies.

Authors:  Paul R Rosenbaum; Jeffrey H Silber
Journal:  J Am Stat Assoc       Date:  2009-12-01       Impact factor: 5.033

8.  Inference with interference between units in an fMRI experiment of motor inhibition.

Authors:  Xi Luo; Dylan S Small; Chiang-Shan R Li; Paul R Rosenbaum
Journal:  J Am Stat Assoc       Date:  2012       Impact factor: 5.033

9.  Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.

Authors:  Deanna L Kelly; Robert P McMahon; Elaine Weiner; Douglas L Boggs; Dwight Dickinson; Robert R Conley; Robert W Buchanan
Journal:  Schizophr Res       Date:  2008-06-11       Impact factor: 4.939

10.  Multiple comparisons in long-term toxicity studies.

Authors:  L Hothorn
Journal:  Environ Health Perspect       Date:  1994-01       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.